15 Best Growth Stocks to Invest in for the Next 5 Years

Page 10 of 13

4. BioLineRx Ltd. (NASDAQ:BLRX)

Upside potential as of June 24, 2025: 483.56%

H.C. Wainwright reaffirmed its Buy rating on BioLineRx Ltd. (NASDAQ:BLRX) while maintaining a price target of $26.00. This confidence follows the company’s participation in ASCO 2025, where the management presented full data from the pilot phase of its CheMo4METPANC Phase 2 trial.

While exhibiting superior efficacy in contrast to historical controls, the outcomes showcased an overall response rate and a disease control rate of 64% and 91%, respectively. What’s even more exciting is that four out of eleven patients remained progression-free even after a year of treatment. While one patient showed a complete radiologic resolution of liver metastases and secured definitive radiation to the primary pancreatic tumor, the other one maintained a sustained partial response, and upon undergoing pancreaticoduodenectomy, a complete response was noted.

These results set the foundation for the company to transform the trial into a randomized Phase 2 study with 108 patients. All of these efforts are a testament to the company’s strong footing in the coming years. Having said that, FTSE Russell recently announced the addition of BioLineRx Ltd. (NASDAQ:BLRX) to the Russell Microcap Index.

BioLineRx Ltd. (NASDAQ:BLRX) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics targeting oncology and rare diseases. Incorporated in 2003, the company is focused on fulfilling unmet medical needs through its drug development efforts.

Page 10 of 13